Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Receivables (2016 - 2025)

CorMedix's Receivables history spans 12 years, with the latest figure at $171.2 million for Q4 2025.

  • For Q4 2025, Receivables rose 231.5% year-over-year to $171.2 million; the TTM value through Dec 2025 reached $171.2 million, up 231.5%, while the annual FY2025 figure was $171.2 million, 231.5% up from the prior year.
  • Receivables for Q4 2025 was $171.2 million at CorMedix, up from $162.6 million in the prior quarter.
  • Across five years, Receivables topped out at $171.2 million in Q4 2025 and bottomed at $2975.0 in Q1 2022.
  • The 4-year median for Receivables is $957206.0 (2025), against an average of $40.7 million.
  • The largest annual shift saw Receivables crashed 93.18% in 2022 before it skyrocketed 5975.24% in 2025.
  • A 4-year view of Receivables shows it stood at $45368.0 in 2021, then tumbled by 93.44% to $2975.0 in 2022, then surged by 1736168.91% to $51.7 million in 2024, then soared by 231.5% to $171.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Receivables are $171.2 million (Q4 2025), $162.6 million (Q3 2025), and $42.9 million (Q2 2025).